OS Therapies Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OS Therapies Incorporated (OSTX) on January 28, 2025. The filing discloses the entry into a Material Definitive Agreement to acquire specific intellectual property assets and the election of a new director to the Board.
Key Financial Metrics and Transaction Details
The filing details an Asset Purchase Agreement with Ayala Pharmaceuticals, Inc. (formerly Advaxis, Inc.) for an aggregate purchase price of $8,000,000. The consideration structure is as follows:
- Cash Payment: $550,000 total ($400,000 to Seller and $100,000 to a third party on behalf of Seller).
- Equity Payment: $7,500,000 in Company common stock (Consideration Shares), valued based on the 30-day volume-weighted average price preceding the Closing Date.
- Warrant Issuance: If the stock issuance causes the Seller to exceed a 9.99% beneficial ownership limit, the Company will issue a warrant for the remaining shares at an exercise price of $0.001 per share, expiring three years from issuance.
The transaction eliminates future milestone and royalty obligations previously owed to Ayala, replacing them with a reduced royalty obligation to the University of Pennsylvania.
Material Changes and Strategic Impact
The acquisition significantly alters the Company's future financial obligations and asset portfolio:
- Asset Acquisition: OS Therapies acquired all HER2 and Listeria monocytogenes (Lm) related IP, including two Investigational New Drug (IND) filings: ADXS-503 (Non-Small Cell Lung Cancer) and ADXS-504 (Prostate Cancer).
- Milestone Elimination: The Company eliminated a $3,500,000 payment due upon FDA Biologics Licensing Authorization for OST-HER2.
- Sales Milestone Elimination: The Company eliminated $16,500,000 in potential future sales milestone payments to Ayala (triggered at $20M, $50M, and $100M cumulative sales).
- Royalty Reduction: Royalty consideration on OST-HER2 sales was reduced from 10% of net sales to Ayala to 1.5% of net sales to the University of Pennsylvania. This 1.5% rate also applies to ADXS-503, ADXS-504, and new Lm platform candidates.
Guidance, Outlook, and Corporate Governance
Corporate Governance: Karim Galzahr was elected to the Board of Directors on January 28, 2025. Mr. Galzahr brings over 30 years of experience in finance, M&A, and life sciences, currently serving as a managing partner at OKG Capital.
Forward-Looking Statements: The filing includes standard cautionary notes regarding risks and uncertainties that could cause actual results to differ from expectations. The Company does not provide specific financial guidance or revenue projections in this document.
Transaction Conditions: Closing is subject to customary conditions, including the assignment of the University of Pennsylvania license, patent assignments, and Ayala stockholder approval.
Investor Verification Checklist
- Verify the final number of Consideration Shares issued based on the 30-day volume-weighted average price at closing.
- Confirm the status of the University of Pennsylvania license assignment and patent transfer agreements.
- Monitor the 180-day lock-up period for the Consideration Shares held by Ayala Pharmaceuticals.
- Review the Registration Rights Agreement to understand the timeline for the resale registration of the issued shares (required within 75 days of closing).
- Assess the clinical status and regulatory pathway for the newly acquired assets ADXS-503 and ADXS-504.